



These projects have received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 963845 (ONTOX), No. 965406 (PrecisionTox), No. 964537 (RISK-HUNT3R)

This output reflects only the author's view and the Directorate-General for Research and Innovation (DG RTD) cannot be held responsible for any use that may be made of the information contained therein.

Open **2-3 July 2026** Symposium

Maastricht
The Netherlands

OECD IATA and ASPA Case Studies: lessons and take home messages

Author's name: Andrew White

Author's affiliation: Unilever

Project: RISK-HUNT3R

aspis-cluster.eu



- The OECD IATA Case Studies Project allows countries to share and explore the use of novel methodologies in IATA for evaluating the safety of chemicals within a regulatory context.
- Within each submission cycle for each approved case studies are published with a consideration documents capture learnings and lessons from the review experience.
- These submissions are time consuming and resource intensive both from the side of the submitters and also the reviewers
- During 2025 5 case studies were submitted - 3 of these were from RiskHunt3r



- Build out from specific independent examples rather than discussing hypotheticals
- Range of stakeholders around the table to get different technical capabilities - method developers, industry and regulators
- Focus on the information and solutions that are being developed in relation to the decision needs
- Demonstrate applicability and utility while also demonstrating gaps in current status
- Enables iteration and improvement

Overarching case studies

RISK
HUNT3R

The **goal** of the case studies is:

- To improve definition of ASPA (sub)modules plus accompanying guidance
- To gain better insight in how to incorporate uncertainty in the application of ASPA
- To contribute to the development of the electronic platform (ASPA dashboard)
- to ultimately demonstrate the applicability of the NGRA strategies developed as well as the utility of ASPA



Master Presentation

Overview General information Tasks Decisions Notes Report Help ⓘ

mirjam ASPIS RISK HUNT3R

Propylparaben case study - consumer exposure scenario

Report date 2025-09-03

Table of Contents

Table of Contents	1
1. General information	2
2. Preliminary	2
2.1 Problem formulation (BB001_01)	2
2.2 Relevant existing data for substance of interest? (BB002_01)	3
2.3 Information sufficient? (DP01EF_01)	4
2.4 Is read-across applicable? (DP02EF_01)	4
3. Hazard	5
3.1 Generate in silico predictions of hazard (BB008_01)	5
3.2 Alert for genotoxicity, eye irritation, skin irritation or sensitization? (DP06EF_01)	6
3.3 Defined approaches and/or dedicated tests to confirm or characterize alert (BB011_01)	6
4. ADME	7

Progress Workflow



- Overall experience was very positive
- Gained first-hand experience of how outputs from the projects can directly drives real-world impact
- IATA emphasizes transparent, accountable reporting of all results

▪


CS 2025-03,4, 5

- ASPA workflow
- OPERA QSAR tool
- VEGA prediction for an inconclusive or out of applicability domain prediction.
- ADME tool
- Chemical Effect Predictor
- Simulation of internal concentrations using Simcyp (webinar)
- TXG-MAPr (webinar)
- KNIME workflow for deriving the model, data transformation and machine learning.

- How to incorporate aggregate exposure estimates and PBK modeling to translate external doses into internal concentrations and apply BER concept
- Which endpoints or responses were examined to assess systemic toxicity
- How to Choose ASPA modules and assess their applicability based on problem formulation assumptions.

"... in a guidance it should be explained how studies should be conducted" "...The biggest problem is how to standardize the tools that generate information sources. Without a set standard, differences will arise between evaluators, leading to variations in the certainty of the results."

" It would assist to have clarification as when to progress to next module or when a person should stop due to being not appropriate or necessary to progress to next module. For example, is there a minimum number of 'positive' bioactivity assays needed to progress




Insufficient detail vs too complex



Progressing IATA for Systemic Toxicity: Examples, frameworks, and guidance to advance evaluation and application

1. Share and discuss outcomes and experiences.
2. Literature scan to characterize available approaches and data
3. Develop an IATA for Repeated-Dose Systemic Toxicity, including criteria for evaluating methods included within IATA.
4. Pilot application of the IATA with existing and novel case studies to demonstrate the variety of tools and use contexts.
5. Review insights from the pilot applications of the evaluation framework to available approaches and develop specific OECD guidance and/or recommend need for further evaluation.



ICCVAM Validation Report, Figure 1
(adapted from van der Zalm et al. 2022 Arch Tox)



One Pilot CS and Three CSs on Systemic Toxicity

Open 2-3 July 2026
Symposium Maastricht
The Netherlands

Title: An Integrated Approach for Testing and Assessment for Systemic Risk Assessment

Versions

- IATA Framework Template – 0.1
- Workflow – 0.5
- Annex II – 0.1
- Annex IIIa – 0.1
- Annex IIIb – 0.1

Modifications to template

- Revised Information Source Table
- Annex I not used
- Annex II modified

Exemplar chemicals evaluated using this IATA Framework

- BP-4
- APCRA - ~200 chemicals

Initial observations:

1. Same endpoint
2. Two different workflows
3. Both applicable to multiple regulatory decisions
4. Chemical agnostic?

Title: Assessment of propylparaben (PrP) from multiple sources using ASPA as an Integrated Approaches for Testing and Assessment (IATA)

IATA Framework Template (IFT) version 03_2025

Deviations:

Chemical evaluated: Propylparaben

Version history

Date
May 13th 2025

Case Study on the Use of Integrated Approaches for Testing and Assessment (IATA) for Systemic Toxicity of Conazoles Using a Read-Across Approach

Barira Islam^{1*}, Jenny Irwan², Lukas Wijaya³, Bas ter Braak⁴, Clemence Budin⁵, Tjalf de Boer⁵, Shu Liu⁶, Marlene Wedler^{6,7}, Baiba Gukalova⁸, Edgars Liepins⁸, Jaione Telleria⁹, Laura Furlong⁹, Nadine Dreser¹⁰, Tanja Hansen², Eva Bay Wedeby¹¹, Vidya Chandrasekaran¹², Paul Jennings¹², Philip Marx-Stoelting⁶, Patrik Lundquist¹³, Hennicke Kamp¹⁴, Mirjam Luijten¹⁵, Bob van de Water³, Andrew White¹⁶, Marcel Leist¹⁰, Iain Gardner¹, Sylvia Escher²

¹ Certara Predictive Technologies, 1 Concourse Way, Level 2-Acero, Sheffield, S1 2BJ, United Kingdom
² Fraunhofer Institute for Toxicology and Experimental Medicine, Chemical Safety and Toxicology, Germany
³ Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands
⁴ Toxys B.V., Leiden Bioscience Park, Oegstgeest, DH 2342, the Netherlands.
⁵ BioDetection Systems, Science Park 406, 1098 XH Amsterdam, The Netherlands
⁶ German Federal Institute for Risk Assessment (BfR), Berlin, Germany
⁷ Institute for Biology, Freie Universität Berlin (BfR), Berlin, Germany
⁸ Latvian Institute of Organic Synthesis
⁹ MedBioinformatics Solutions, Rambla de Catalunya 14, 7º, 1º, 08007 Barcelona, Spain
¹⁰ Department of in vitro toxicology and biomedicine, Faculty of Sciences, University of Konstanz,

IATA Case Study on Prioritization and Screening of compounds for Systemic Toxicity

Authors:
Matthias Wehr¹, Barira Islam¹, Lukas Wijaya³, Oliver Pötz², Helen Hammer², Edgar Liepins⁸, Wedeby¹¹, Vidya Chandrasekaran¹², Lundquist¹³, Swenil Chandra¹⁴, Marcel Leist¹⁰, Iain Gardner¹, Sylvia Escher²

Clemence Budin⁵, Tjalf de Boer⁵, Shu Liu⁶, Laura Furlong⁹, Tanja Hansen², Eva Bay Wedeby¹¹, Philip Marx-Stoelting⁶, Patrik Lundquist¹³, Hennicke Kamp¹⁴, Mirjam Luijten¹⁵, Bob van de Water³, Andrew White¹⁶, Sylvia Escher²

S1 2BJ, United Kingdom
Toxicology,
Leiden University,





SysTox Workflow vs ASPA workflow

23 July 2026

Initial observations:


1. Mostly same fundamental concepts: exposure driven, NAM-based
2. Similar modules differently defined
3. Flexible vs more prescriptive steps





In combination ASPA case studies and the IATA project can both contributed to advancing the nto more general context-dependent guidance to start to bridge the gap between one-off case studies + general IATA - avoid the “it depends”

- **Workflow Harmonisation:** Aim prioritise areas for harmonise the OECD IATA and ASPA workflows, focusing on commonalities and integrating best practices.
- **Guidance Integration:** Review and incorporate relevant guidance and learnings from ASPA (including the handbook and assist tool) into the OECD IATA framework, ensuring consistency and leveraging existing materials
- **Benchmarking and Acceptance Criteria:** Develop conceptual criteria for regulatory acceptance and benchmarking of NAM-based risk assessments, considering variability and uncertainties in both animal and in vitro data.





RISK [:::] HUNT3R

Barira Islam

Gladys Ouderago

Sylvia Escher

Mirjam Luijten



Lead organizations/countries and main contacts:

ICAPO: Eryn Slankster-Schmierer

United States: Nicole Kleinstreuer

Canada: Tara Barton-Maclaren

Other team members:

Canada: Kristin Eccles, Matthew Gagne, HealthCanada

ICAPO:

Kristie Sullivan, IIVS

Shagun Krishna, PCRM

Donna Macmillan, Dave Allen, **ICCS**

BIAC:

Maria Baltazar, Andrew White, Unilever

United States: Brad Reisfeld, Inotiv/NICEATM